A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception [clinicaltrials:NCT00185419]

Bio2RDF namespace

clinicaltrials

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00185419

identifiers.org URI

NCT00185419

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

842

NCT00185419 arm group 0a6e71b1034abcd1f2d32e915b9fecee [clinicaltrials_resource:NCT00185419/arm-group/0a6e71b1034abcd1f2d32e915b9fecee]

arm group [clinicaltrials_vocabulary:arm-group]

NCT00185419 arm group 3f237303121a9d19106f8a7fd915e494 [clinicaltrials_resource:NCT00185419/arm-group/3f237303121a9d19106f8a7fd915e494]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:245b0106e3be1922b847a6799a540c10

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... n healthy Chinese women

brief title [clinicaltrials_vocabulary:brief-title]

A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception

The primary efficacy variable is the comparison of cycle control from randomisation to cycle 13. This will be based on the number of subjects reporting at least 1 unexpected intracyclic bleeding episode between cycles 2 to 13. 13 treatment cycles (1 cycle= 28 days) [clinicaltrials_resource:3e598af62432f4f6bbc2792ab1a6fcbf]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

The primary efficacy variable is the comparison of cycle control from randomisation to cycle 13. This will be based on the number of subjects reporting at least 1 unexpected intracyclic bleeding episode between cycles 2 to 13. 13 treatment cycles (1 cycle= 28 days) [clinicaltrials_resource:08fe8760b68185da51a14efb03a22edc]

The primary efficacy variable is the comparison of cycle control from randomisation to cycle 13. This will be based on the number of subjects reporting at least 1 unexpected intracyclic bleeding episode between cycles 2 to 13. 13 treatment cycles (1 cycle= 28 days) [clinicaltrials_resource:4c95761897c918419001a57f7d190b92]

The primary efficacy variable is the comparison of cycle control from randomisation to cycle 13. This will be based on the number of subjects reporting at least 1 unexpected intracyclic bleeding episode between cycles 2 to 13. 13 treatment cycles (1 cycle= 28 days) [clinicaltrials_resource:b4bd76083e8960e5dc925b5ff21157b1]

The primary efficacy variable is the comparison of cycle control from randomisation to cycle 13. This will be based on the number of subjects reporting at least 1 unexpected intracyclic bleeding episode between cycles 2 to 13. 13 treatment cycles (1 cycle= 28 days) [clinicaltrials_resource:e0dcd1ece52afe65f048a96cdb8f36d0]

The primary efficacy variable is the comparison of cycle control from randomisation to cycle 13. This will be based on the number of subjects reporting at least 1 unexpected intracyclic bleeding episode between cycles 2 to 13. 13 treatment cycles (1 cycle= 28 days) [clinicaltrials_resource:f48d354ab1b421918786dfbbaa45ebcf]

completion date [clinicaltrials_vocabulary:completion-date]

2006-03-01T00:00:00Z

Contraception [clinicaltrials_resource:5ed3369a9d182d8ce53df32b37b15c9b]

condition [clinicaltrials_vocabulary:condition]

country [clinicaltrials_vocabulary:country]

China [clinicaltrials_resource:ae54a5c026f31ada088992587d92cb3a]

detailed description [clinicaltrials_vocabulary:detailed-description]

The study has previousl ...... is the sponsor of the trial.

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

eligibility for clinicaltrials:NCT00185419 [clinicaltrials_resource:cfd44a21044797eec715354c22c3be30]

eligibility [clinicaltrials_vocabulary:eligibility]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-13T00:00:00Z

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

Marvelon [clinicaltrials_resource:02537c2ab152e7ac3c97d46442d748f9]

intervention [clinicaltrials_vocabulary:intervention]

Yasmin [clinicaltrials_resource:129836bc16fa2e4e6f181394b968039a]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Ethinyl Estradiol [clinicaltrials_resource:8d8be834408fc83e7b63513fab54c6b0]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

is section 801 [clinicaltrials_vocabulary:is-section-801]

No

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2009-01-13T00:00:00Z

nct id [clinicaltrials_vocabulary:nct-id]

NCT00185419

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

official title [clinicaltrials_vocabulary:official-title]

An Open-Label, Randomised, Par ...... y Chinese Women Over 13 Cycles

org study id [clinicaltrials_vocabulary:org-study-id]

91,330

Bayer Study Director [clinicaltrials_resource:b1c1f90b6ec7129e1a428d16e9b32e7c]

overall official [clinicaltrials_vocabulary:overall-official]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

China: Food and Drug Administration [clinicaltrials_resource:f4f0ea17617afc755400c6bca8ea78a5]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2006-03-01T00:00:00Z

Therapeutic Area Head, Bayer Schering Pharma AG [clinicaltrials_resource:3406bd37433a688bfdd2c46c96f36822]

responsible party [clinicaltrials_vocabulary:responsible-party]

secondary id [clinicaltrials_vocabulary:secondary-id]

308,062

Bayer [clinicaltrials_resource:d4ff4823ac2f6adeccc0e9df435e2e20]

source [clinicaltrials_vocabulary:source]

start date [clinicaltrials_vocabulary:start-date]

2003-11-01T00:00:00Z

clinicaltrials:NCT00185419 study design [clinicaltrials_resource:1939fe3100e094ef408e462157092d65]

study design [clinicaltrials_vocabulary:study-design]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00185419

verification date [clinicaltrials_vocabulary:verification-date]

2009-01-01T00:00:00Z

identifier

clinicaltrials:NCT00185419